Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice

NCT00787319

Last updated date
Study Location
Pfizer Investigational Site
Brno, , 625 00, Czechia
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Age-related Macular Degeneration
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- age over 18 years old

- patients with neovascular age-related macular degeneration

- enrollment to study is fully on physician decision in compliance with current SPC

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patient who did not meet indication according to SPC Macugen.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Age-Related Macular DegenerationA Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration NCT00090532
  1. Mesa, Arizona
  2. Oro Valley, Arizona
  3. Phoenix, Arizona
  4. Sun City, Arizona
  5. Tucson, Arizona
  6. Tuscon, Arizona
  7. Beverly Hills, California
  8. Fort Myers, Florida
  9. Tampa, Florida
  10. Iowa City, Iowa
  11. Chevy Chase, Maryland
  12. Hagerstown, Maryland
  13. Boston, Massachusetts
  14. Ann Arbor, Michigan
  15. Livonia, Michigan
  16. Rochester, Michigan
  17. Royal Oak, Michigan
  18. St. Clair Shores, Michigan
  19. Ypsilanti, Michigan
  20. Slingerlands, New York
  21. Charlotte, North Carolina
  22. Huntersville, North Carolina
  23. Cleveland, Ohio
  24. Lakewood, Ohio
  25. Portland, Oregon
  26. Chambersburg, Pennsylvania
  27. Columbia, South Carolina
  28. Knoxville, Tennessee
  29. Houston, Texas
  30. Fairfax, Virginia
  31. Sydney, New South Wales
  32. East Melbourne, Victoria
  33. Nijmegen, Gld
  34. Groningen, GR
  35. Amsterdam, NH
  36. Rotterdam, ZH
  37. Aberdeen, Scotland
  38. Bristol,
  39. London,
ALL GENDERS
55 Years+
years
MULTIPLE SITES
Age-related Macular DegenerationLong-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice NCT00787319
  1. Brno,
  2. Brno,
  3. Olomouc,
  4. Olomouc,
  5. Ostrava - Poruba,
  6. Plzen,
  7. Praha 2,
  8. Praha 2,
  9. Praha 6,
  10. Praha 6,
  11. Usti nad Labem,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice
Official Title Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice
Brief Summary To define what procedures were used for the diagnosis and monitoring of the treatment age-related macular degeneration (AMD). What is the effect of the Macugen, compliance with Macugen treatment, safety profile of Macugen, final physician assessment of treatment with Macugen.
Detailed Description no sampling
Study Type Observational
Study Design Observational Model: Case-Control
Time Perspective: Cross-Sectional
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population outpatients
Condition Age-related Macular Degeneration
Intervention Other: no intervention
Outpatients with age-related macular degeneration (AMD)
Other Name: observation only
Study Groups/Cohorts AMD
Intervention: Other: no intervention
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: July 20, 2012)
108
Original Estimated Enrollment
 (submitted: November 6, 2008)
120
Actual Study Completion Date June 2012
Actual Primary Completion Date June 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • age over 18 years old
  • patients with neovascular age-related macular degeneration
  • enrollment to study is fully on physician decision in compliance with current SPC

Exclusion Criteria:

  • Patient who did not meet indication according to SPC Macugen.
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Czechia
Removed Location Countries Czech Republic
 
Administrative Information
NCT Number NCT00787319
Other Study ID Numbers A5751032
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2018